The DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.
Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation
Open accessAbstract
BACKGROUND: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics and among the most misused and abused medications by patients, in parallel with opioids. It is estimated that more than 100 million Benzodiazepine (BZD) prescriptions were written in the United States in 2009. While medically useful, BZDs are potentially dangerous. The co-occurring abuse of opioids and BZD, as well as increases in BZD abuse, tolerance, dependence, and short- and long-term side effects, have prompted a worldwide discussion about the challenging aspects of medically managing the discontinuation of BZDs. Abrupt cessation can cause death. This paper addresses the challenges of medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse and associated medical complications. The focus of this review is on the challenges of several medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse, and associated medical complications. METHODS: An electronic search was performed of Medline, Worldwide Science, Directory of Open Access Journals, Embase, Cochrane Library, Google Scholar, PubMed Central, and PubMed from 1990 to 2017. The review includes double-blind, placebo-controlled studies for the most part, open-label pilot studies, and animal studies, in addition to observational research. We expand the search to review articles, naturalistic studies, and to a lesser extent, letters to the editor/case reports. We exclude abstract and poster presentations, books, and book chapters. RESULTS: The efficacy of these medications is not robust. While some of these medicines are relatively safe to use, some of them have a narrow therapeutic index, with severe, life-threatening side effects. Randomized studies have been limited. There is a paucity of comparative research. The review has several limitations. The quality of the documents varies according to whether they are randomized studies, nonrandomized studies, naturalistic studies, pilot studies, letters to the editors, or case reports. CONCLUSIONS: The use of medications for the discontinuation of BZDs seems appropriate. It is a challenge that requires further investigation through randomized clinical trials to maximize efficacy and to minimize additional risks and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benzodiazepines are also incredibly effective at rapidly aborting convulsant activity in those with epilepsy or other seizure disorders [5].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently, the number of individuals seeking treatment for complications related to BZD use dependence is rising [5].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub2 · Cited by 150
RetractedBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Benzodiazepine pharmacology and central nervous system-mediated effects.
(2013) · Europe PMC (PubMed Central) · Cited by 650
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05996.x · Cited by 591
Taylor, C. P., Angelotti, T., & Fauman, E. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.09.008 · Cited by 565
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531
Clinical Pharmacokinetics of Diazepam
Mandelli, M., Tognoni, G., & Garattini, S. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803010-00005 · Cited by 496
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Research works printed but not linked: 23
- Pal R, 2015, The ASAM essential of addiction medicine, 53
- SAMSHA, 2012, The DAWN report: highlights of the 2010 Drug Abuse Warning Network finding in drug-related emergency department visits
- Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
- Griffin CE, 2013, Ochsner J, 13, 214
- Sieghart W., 1994, J Psychiatry Neurosci, 19, 24
- Meibach RC, 1987, J Clin Psychiatry, 48, 355
- King TL, Brucker MC. Pharmacology for women’s health. 2nd ed. Sudbury: Jones & Bartlett Publishers, 2010, pp.372–373.
- Ng F, 2007, Neuropsychiatr Dis Treat, 3, 463
- Birkhimer LJ, 1985, Clin Pharm, 4, 425
- Kasson BJ., 1992, J Am Assoc Nurse Anesth, 60, 464
- Griffin CE, 2013, Ochsner J, 13, 214
- Comai S, 2013, Brain Res, 243, 231
- Faccini M, 2012, Risk Manag Healthc Policy, 5, 43
- Olsen RW, DeLorey TM. GABA receptor physiology and pharmacology. Basic neurochemistry: molecular, cellular and medical aspects. Lippincott-Raven, https://www.ncbi.nlm.nih.gov/books/NBK28090 (1999, accessed May 2017).
- Kumar AA, 2014, Int J Pharm Bio Sci, 5, 1
- 10.18773/austprescr.2015.055 · DOI · Paper page
- James J., 2016, Aust Prescr, 39, 96
- 10.1001/jama.1987.03390040137034 · doi:10.1001/jama.1987.03390040137034
- Patterson JF, 1990, J Clin Psychiatry, 51, 47
- Hantouche EG, 1998, Encephale, 24, 469
- Chandrasekaran PK., 2008, Singapore Med J, 49, 166
- 10.1007/BF02246214 · DOI
- 10.1007/s00228-001-0387-4 · DOI · Paper page
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“Currently, the number of individuals seeking treatment for complications related to BZD use dependence is rising [5].”
BackgroundBenzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective
Goldschen-Ohm, M. P. (2022) · Biomolecules · doi:10.3390/biom12121784 · Cited by 145
“Although largely successful, the prolonged use of BZDs can have undesirable side effects, including tolerance, dependence, withdrawal, and cognitive impairment [3,4].”
BackgroundKava as a Clinical Nutrient: Promises and Challenges
Bian, T., Corral, P., Wang, Y., Botello, J. F., Kingston, R., Daniels, T. F., Salloum, R. G., Johnston, E., Huo, Z., Lü, J., et al. (2020) · Nutrients · doi:10.3390/nu12103044 · Cited by 110
“At the same time, stress and anxiety are becoming more prevalent among the general population [174], while current pharmacologic treatments have only a modest clinical effect and carry a high burden of side effects [175,176].”
BackgroundGABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 94
“, equivalent of 100mg diazepam per day or more), hospitalization during the withdrawal period and pharmacological management of the symptoms is recommended (145, 146).”
BackgroundBenzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 85
Metadata
- Authors
- Fluyau, D., Revadigar, N., & Manobianco, B. E.
- Affiliations
- Emory University (US)
- Columbia University (US)
- Corresponding author
- Fluyau, Dimy
- ORCID
- Fluyau, Dimy
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-02-09
- Volume
- 8
- Issue
- 5
- Pages
- 147-168
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC5896864
- OpenAlex
- W2793118967
- Cited by
- 109
- References
- 107
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 8 · 2023: 15 · 2022: 19 · 2021: 18 · 2020: 14 · 2019: 8 · 2018: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine discontinuation, pharmacological management, benzodiazepine misuse, drug tolerance, adverse effects, narrow therapeutic index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. https://app.cochat.ai/papers/10.1177/2045125317753340
- The paper
- Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018). Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125317753340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.